Effect of pemetinib/pemetinib combined with camrelizumab

Pemigatinib/Pemigatinib is a targeted therapy drug mainly used to treat advanced cholangiocarcinoma with FGRF gene mutations. The programmed cell death 1 (PD-1) inhibitor Camrelizumab being developed by Jiangsu Hengrui Pharmaceutical Co., Ltd. recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being studied for the treatment of various other malignant tumors, including gastric/gastroesophageal junction cancer, hepatocellular carcinoma, etc.

Pemetinib is a targeted drug that mainly targets fibroblast growth factor receptor (FGFR), while camrelizumab is an immune checkpoint inhibitor that enhances the immune system's attack on tumors by inhibiting programmed death receptor-1 (PD-1). Theoretically, the combined use of these two drugs may have a synergistic effect, both inhibiting tumor growth and proliferation and enhancing the immune system's anti-tumor response. Several preliminary clinical studies and trials are exploring the possibility of combining pemetinib with camrelizumab. The purpose of these studies is to evaluate the safety, efficacy, and potential benefits of combination therapy.

The therapeutic effect of pemetinib combined with camrelizumab will be affected by many factors, including individual differences among patients, tumor characteristics, and the specific design of the treatment plan. At present, further clinical research and data are needed to evaluate the effect of the combined use of these two drugs. However, treatment for advanced cholangiocarcinoma usually involves a variety of different treatments, including surgery, chemotherapy, targeted therapy, and immunotherapy. The doctor will develop the most appropriate treatment plan based on the patient's specific situation.